---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-038605"
form_type: "8-K"
ticker: "OWLT"
cik: "0001816708"
company_name: "Owlet, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:22:44.886874+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Owlet Q3 2023 revenue $9.2M, net loss $5.6M; FDA clears Dream Sock OTC

## Summary
- Q3 revenue $9.2M, down 47% YoY due to shift to Amazon first-party seller; sell-in shifted to Q4.
- Net loss narrowed to $5.6M ($0.84/sh) from $19.4M ($2.42/sh) in Q3 2022.
- Gross margin improved to 36.3% from 26.6%; operating expenses cut to $11.2M from $26.4M.
- FDA de novo authorization for Dream Sock as first OTC pulse oximeter for healthy infants; launch by Dec 2023.
- BabySat monitoring system market introduction began; commercial launch target by end of 2023.

## SEC filing metadata
- accession: 0001628280-23-038605
- form_type: 8-K
- ticker: OWLT
- cik: 0001816708
- company_name: Owlet, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816708/000162828023038605/0001628280-23-038605-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816708/000162828023038605/owlt-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-038605
- JSON: https://secwatch.observer/filing/0001628280-23-038605.json
- Plain text: https://secwatch.observer/filing/0001628280-23-038605.txt

## Key facts
- Earnings Releases
  Owlet, Inc. reported third quarter ended September 30, 2023 results: revenue $9.2 million, net income $5.6 million, EPS $(0.84).
  - Period: third quarter ended September 30, 2023
  - Revenue: $9.2 million
  - Net income: $5.6 million
  - EPS: $(0.84)
  - Result: reported results
  source text: Sock® – the first and only over-the-counter, medical grade pulse oximeter classified by FDA for healthy infants and preparing for launch by December 2023. · Achieved revenues of $9.2 million as the Company entered into a new arrangement to start selling products directly to Amazon.com, Inc. under a first-party seller relationship shifting Amazon revenues into Q4. ·
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816708/000162828023038605/0001628280-23-038605-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.